Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon

 
• By Bridget Silverman
Keeping Track Feature image
Busy week included approval of Apellis’ age-related macular degeneration treatment and an application for the first China-developed biosimilar in the US.

More from United States

More from North America